Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adefovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | POLG | P54098 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.53 |
| ▸ | NSD2 | O96028 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adefovir SCHEMBL29064626 | 1.00 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL28765885 | 1.00 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL49373 | 0.99 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29365535 | 0.99 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29115272 | 0.97 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL28511793 | 0.97 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL28571494 | 0.97 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL3643715 | 0.97 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL3639260 | 0.97 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL439994 | 0.94 | FGFR1 (0.91) | FGFR1SLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119881137-A | Method and kit for detecting ultrahigh-polarity amphoteric compound on dry blood spot | 裕菁科技(上海)有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20220307066-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2022-09-29 | — | — | US | claimed |
| WO-2020252399-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2020-12-17 | — | — | WO | claimed |
| US-20100167268-A1 | SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS | WHITTEMORE PETERSON INSTITUTE | 2010-07-01 | — | — | US | claimed |
| US-7611704-B2 | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-03 | — | — | US | claimed |
| US-7511124-B2 | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-03-31 | — | — | US | claimed |
| US-7455833-B2 | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-11-25 | — | — | US | claimed |
| US-7384909-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-10 | — | — | US | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | A-BIOPHARMA (FR) | 2026-02-03 | — | — | US | disclosed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024085557-A1 | COMPOSITION FOR PREVENTING OR TREATING OSCAR-INDUCED DISEASES, COMPRISING ADEFOVIR AS ACTIVE INGREDIENT | 주식회사 카이팜 | 2024-04-25 | — | — | WO | disclosed |
| CN-117482101-A | Application of gemcitabine hydrochloride in preparation of medicines for preventing and/or treating alcoholic gastric ulcer | 兰州大学 | 2024-02-02 | — | — | CN | disclosed |
| WO-2004031224-A2 | HBV MUTATIONS ASSOCIATED WITH REDUCED SUSCEPTIBILITY TO ADEFOVIR | GILEAD SCIENCES, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031729-A2 | DIAGNOSTIC FOR LONG TERM RESPONSE OF HBV CARRIER TO 3TC THERAPY | GEORGETOWN UNIVERSITY (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004024095-A2 | ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | IDENIX (CAYMAN) LIMITED (KY) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004006848-A2 | COMBINATION THERAPIES WITH FTC FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES , INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006843-A2 | COMBINATION THERAPIES WITH L-FMAU FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003080078-A1 | TREATMENT OF PRE-CORE HEPATITIS B VIRUS MUTANT INFECTIONS | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | HAVCR2, NR1H4, NR1H3 | FGFR1 1576/4885SLC22A6 752/4885ABCB11 30/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | FGFR1 1377/4885SLC22A6 631/4885ABCB11 34/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | FGFR1 2545/4885SLC22A6 149/4885ABCB11 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.